caa a22 4500 463255380 CHVBK 20180405153353.0 cr unu---uuuuu 170326e20070101xx s 000 0 eng 10.1007/s00277-006-0190-5 doi (NATIONALLICENCE)springer-10.1007/s00277-006-0190-5 Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan [Elektronische Daten] [Tsunehiko Komatsu, Hiroto Narimatsu, Ai Yoshimi, Naoki Kurita, Manabu Kusakabe, Akiko Hori, Naoko Murashige, Tomoko Matsumura, Kazuhiko Kobayashi, Koichiro Yuji, Yuji Tanaka, Masahiro Kami] We conducted a pilot study to evaluate the feasibility of reduced-intensity cord blood transplantation (RI-CBT) using a non-total body irradiation (TBI) regimen in adult patients with advanced hematologic malignancies. Seventeen patients with a median age of 58years (range, 38-74) underwent RI-CBT at Tsukuba Memorial Hospital between April 2004 and November 2005. Preparative regimens were fludarabine 30mg/m2 for 6days, and busulfan 4mg/kg for 2days. Tacrolimus was used for prophylaxis of graft-vs-host disease (GVHD). Median numbers of infused total nucleated were 2.6×107/kg (range, 2.0-3.3). HLA disparity was found in 2/6 antigens (n=16) and 1/6 antigens (n=1). Underlying diseases progressed despite preparative regimens in four patients. Of the remaining 13 patients, nine patients achieved engraftment at a median of day18 (range, 17-28). Six of the nine patients with engraftment achieved complete donor-type chimerism by day100. Six patients were alive in remission at median follow-up of 13.1months (range, 1.0-19.0). This study demonstrated the feasibility of RI-CBT using a non-TBI regimen in adults. When disease progression is controlled by the preparative regimen, RI-CBT carries a clinically significant graft-vs-tumor effect. Further studies are required to identify patients who benefit from this regimen. Springer-Verlag, 2006 Reduced intensity stem cell transplantation nationallicence Umbilical cord blood nationallicence Engraftment nationallicence Total body irradiation nationallicence Fludarabine nationallicence Tacrolimus nationallicence Komatsu Tsunehiko Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut Narimatsu Hiroto Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan aut Yoshimi Ai Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut Kurita Naoki Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut Kusakabe Manabu Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut Hori Akiko Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut Murashige Naoko Department of Hematology, JR Tokyo General Hospital, Tokyo, Japan aut Matsumura Tomoko Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut Kobayashi Kazuhiko Department of Hematology, JR Tokyo General Hospital, Tokyo, Japan aut Yuji Koichiro Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut Tanaka Yuji Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut Kami Masahiro Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut Annals of Hematology Springer-Verlag 86/1(2007-01-01), 49-54 0939-5555 86:1<49 2007 86 277 https://doi.org/10.1007/s00277-006-0190-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00277-006-0190-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Komatsu Tsunehiko Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut NATIONALLICENCE 700 1- Narimatsu Hiroto Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan aut NATIONALLICENCE 700 1- Yoshimi Ai Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut NATIONALLICENCE 700 1- Kurita Naoki Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut NATIONALLICENCE 700 1- Kusakabe Manabu Department of Hematology, Tsukuba Memorial Hospital, Tsukuba, Japan aut NATIONALLICENCE 700 1- Hori Akiko Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut NATIONALLICENCE 700 1- Murashige Naoko Department of Hematology, JR Tokyo General Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Matsumura Tomoko Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut NATIONALLICENCE 700 1- Kobayashi Kazuhiko Department of Hematology, JR Tokyo General Hospital, Tokyo, Japan aut NATIONALLICENCE 700 1- Yuji Koichiro Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut NATIONALLICENCE 700 1- Tanaka Yuji Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut NATIONALLICENCE 700 1- Kami Masahiro Division of Exploratory Research, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan aut NATIONALLICENCE 773 0- Annals of Hematology Springer-Verlag 86/1(2007-01-01), 49-54 0939-5555 86:1<49 2007 86 277 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer